Leerink Partners analyst David Risinger maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $28.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
David Risinger has given his Hold rating due to a combination of factors affecting Pfizer’s financial outlook. While management has been effective in surpassing expectations, the company’s future growth prospects hinge on upcoming pipeline developments. Pfizer’s recent financial performance was strong, but there remains uncertainty regarding long-term earnings growth, with a forecasted negative compound annual growth rate from 2025 to 2030.
Additionally, Pfizer has several important clinical trial readouts expected in 2025 that could potentially influence future earnings and revenue. The company’s plans for external business development and its intention to reduce leverage might improve its growth trajectory. However, until these developments materialize and provide clearer guidance on future performance, maintaining a Hold rating seems prudent.
According to TipRanks, Risinger is a 5-star analyst with an average return of 12.5% and a 57.76% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Bristol-Myers Squibb.
In another report released yesterday, TD Cowen also maintained a Hold rating on the stock with a $32.00 price target.